BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28284200)

  • 1. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial.
    Sullivan FM; Farmer E; Mair FS; Treweek S; Kendrick D; Jackson C; Robertson C; Briggs A; McCowan C; Bedford L; Young B; Vedhara K; Gallant S; Littleford R; Robertson J; Sewell H; Dorward A; Sarvesvaran J; Schembri S
    BMC Cancer; 2017 Mar; 17(1):187. PubMed ID: 28284200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging.
    Sullivan FM; Mair FS; Anderson W; Armory P; Briggs A; Chew C; Dorward A; Haughney J; Hogarth F; Kendrick D; Littleford R; McConnachie A; McCowan C; McMeekin N; Patel M; Rauchhaus P; Ritchie L; Robertson C; Robertson J; Robles-Zurita J; Sarvesvaran J; Sewell H; Sproule M; Taylor T; Tello A; Treweek S; Vedhara K; Schembri S;
    Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32732334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of direct referral for fast CT scan in early lung cancer detection in general practice. A clinical, cluster-randomised trial.
    Guldbrandt LM
    Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer.
    Field JK; Duffy SW; Baldwin DR; Brain KE; Devaraj A; Eisen T; Green BA; Holemans JA; Kavanagh T; Kerr KM; Ledson M; Lifford KJ; McRonald FE; Nair A; Page RD; Parmar MK; Rintoul RC; Screaton N; Wald NJ; Weller D; Whynes DK; Williamson PR; Yadegarfar G; Hansell DM
    Health Technol Assess; 2016 May; 20(40):1-146. PubMed ID: 27224642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation.
    Duarte A; Corbett M; Melton H; Harden M; Palmer S; Soares M; Simmonds M
    Health Technol Assess; 2022 Dec; 26(49):1-184. PubMed ID: 36534989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of optimised patient information materials on recruitment in a lung cancer screening trial: an embedded randomised recruitment trial.
    Parker A; Knapp P; Treweek S; Madhurasinghe V; Littleford R; Gallant S; Sullivan F; Schembri S; Rick J; Graffy J; Collier DJ; Eldridge S; Kennedy A; Bower P
    Trials; 2018 Sep; 19(1):503. PubMed ID: 30227890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules.
    Edelsberg J; Weycker D; Atwood M; Hamilton-Fairley G; Jett JR
    PLoS One; 2018; 13(5):e0197826. PubMed ID: 29787590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of the EarlyCDT® Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort.
    Borg M; Wen SWC; Nederby L; Hansen TF; Jakobsen A; Andersen RF; Weinreich UM; Hilberg O
    Lung Cancer; 2021 Aug; 158():85-90. PubMed ID: 34130044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a new autoantibody test added to Computed Tomography (CT) compared to CT surveillance alone in the diagnosis of lung cancer amongst patients with indeterminate pulmonary nodules.
    Sutton AJ; Sagoo GS; Jackson L; Fisher M; Hamilton-Fairley G; Murray A; Hill A
    PLoS One; 2020; 15(9):e0237492. PubMed ID: 32877432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice.
    Jett JR; Peek LJ; Fredericks L; Jewell W; Pingleton WW; Robertson JF
    Lung Cancer; 2014 Jan; 83(1):51-5. PubMed ID: 24268382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
    Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers.
    Horeweg N; Scholten ET; de Jong PA; van der Aalst CM; Weenink C; Lammers JW; Nackaerts K; Vliegenthart R; ten Haaf K; Yousaf-Khan UA; Heuvelmans MA; Thunnissen E; Oudkerk M; Mali W; de Koning HJ
    Lancet Oncol; 2014 Nov; 15(12):1342-50. PubMed ID: 25282284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
    Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
    J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum and blood based biomarkers for lung cancer screening: a systematic review.
    Chu GCW; Lazare K; Sullivan F
    BMC Cancer; 2018 Feb; 18(1):181. PubMed ID: 29439651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.
    Chapman CJ; Healey GF; Murray A; Boyle P; Robertson C; Peek LJ; Allen J; Thorpe AJ; Hamilton-Fairley G; Parsy-Kowalska CB; MacDonald IK; Jewell W; Maddison P; Robertson JF
    Tumour Biol; 2012 Oct; 33(5):1319-26. PubMed ID: 22492236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening.
    Field JK; Duffy SW; Baldwin DR; Whynes DK; Devaraj A; Brain KE; Eisen T; Gosney J; Green BA; Holemans JA; Kavanagh T; Kerr KM; Ledson M; Lifford KJ; McRonald FE; Nair A; Page RD; Parmar MK; Rassl DM; Rintoul RC; Screaton NJ; Wald NJ; Weller D; Williamson PR; Yadegarfar G; Hansell DM
    Thorax; 2016 Feb; 71(2):161-70. PubMed ID: 26645413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early detection of lung cancer in Czech high-risk asymptomatic individuals (ELEGANCE): A study protocol.
    Lambert L; Janouskova L; Novak M; Bircakova B; Meckova Z; Votruba J; Michalek P; Burgetova A
    Medicine (Baltimore); 2021 Feb; 100(5):e23878. PubMed ID: 33592843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct and indirect healthcare costs of lung cancer CT screening in Denmark: a registry study.
    Jensen MD; Siersma V; Rasmussen JF; Brodersen J
    BMJ Open; 2020 Jan; 10(1):e031768. PubMed ID: 31969362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.